MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Cognitive dysfunction"

  • 2017 International Congress

    Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease

    G. Pagano, T. Yousaf,, C. Loane, S. Polychronis, H. Wilson, B. Giordano, F. Niccolini, M. Politis (London, United Kingdom)

    Objective: We investigated which clinical-ready and cost-effective markers are predictive of cognitive impairment (CI) in Parkinson’s disease (PD) in a cohort of 294 patients with…
  • 2017 International Congress

    Cognitive Function is Preserved 10 Years Following DBS in People with Dystonia

    E. Hogg, J. Eskenazi, E. During, J. Wertheimer, R. Alterman, M. Tagliati (Los Angeles, CA, USA)

    Objective: To study cognitive function in people with dystonia chronically treated with Deep Brain Stimulation (DBS). Background: The impact of DBS on cognition is a matter of…
  • 2017 International Congress

    Cognitive changes and cortical thinning evolution of parkinson’s disease patients: 4-year-follow up.

    A. Campabadal, C. Uribe, B. Segura, H. Baggio, A. Abos, A. Garcia-Diaz, M.-J. Marti, Y. Compta, F. Valldeoriola, C. Junque (Barcelona, Spain)

    Objective: The aim of the study was to investigate differences in the progression of cognitive decline and cortical thinning evolution in Parkinson’s disease (PD) patients…
  • 2017 International Congress

    Cognitive Impairment in MSA Patients from the Catalan Multiple System Atrophy Registry (CMSAR)

    D. Giraldo, Y. Compta, F. Antonelli, E. Muñoz, A. Camara, J. Pagonabarraga, O. de Fabregués, J. Hernández-Vara, F. Valldeoriola, E. Tolosa, M.C. Pont, S. Jauma, A. Bayes, N. Caballol, M. Calopa, P. Pastor, L. Planellás, M. Pujol, V. Puente, A. Avila, M.J. Martí (Barcelona, Spain)

    Objective: To assess the cognitive function and its demographic and clinical correlates in MSA patients included in the Catalan Multiple System Atrophy-Registry (CMSAR). Background: Cognitive…
  • 2017 International Congress

    Association of CSF biomarkers with motor and non-motor features in moderately advanced Parkinson’s disease cohort: the BioFIND study

    J. Goldman, A. Amara, L. Shaw, P. Taylor, H. Andrews, R. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, S. Frank, M.-H. Saint Hilaire, A. Naito, M. Frasier, V. Arnedo, A. Reimer, M. Sutherland, C. Swanson-Fischer, K. Gwinn, U. Kang (Chicago, IL, USA)

    Objective: Evaluate associations between CSF biomarkers of neurodegeneration and clinical phenotype in Parkinson’s disease (PD) participants of the BioFIND cohort.  Background: Levels of CSF α-synuclein…
  • 2017 International Congress

    Adding cues to a rat gambling task potentiates the increase in premature responding in response to chronic D2/3 agonist ropinirole without mitigating preference for risk

    M. Tremblay, M. Barrus, P. Cocker, S. Kaur, C. Winstanley (Vancouver, BC, Canada)

    Objective: Investigating the effect of chronic administration of the dopamine D2/3 agonist ropinirole on a cued model of gambling behaviour in rats.  Background: Dopamine D2/3 agonists…
  • 2017 International Congress

    High systolic blood pressure is associated with cognitive impairment in Parkinson’s disease (PD)

    H. Chan, Y. Cheung, T. Fung, A. Leung, W. Fong (Hong Kong, Hong Kong)

    Objective: To assess if metabolic risk factors are associated with cognitive dysfunction in PD patients. Background: Metabolic syndrome is known as a risk factor of many…
  • 2017 International Congress

    Cognition in the PREDICT-PD Cohort

    A. Nagy, E. Hardaker, J. Bestwick, G. Giovannoni, T. Warner, A. Lees, A. Schrag, A. Noyce (London, United Kingdom)

    Objective: To identify whether there is evidence for cognitive dysfunction in participants identified as being at higher risk of Parkinson’s disease (PD) using the PREDICT-PD…
  • 2017 International Congress

    Classification of neurocognitive impairment in Spanish speaking Parkinson’s disease patients

    S. Anderson, C. Bermudez, N. Sun-Suslow, L. Segala, H. Moore, C. Singer, J. Jagid, G. Rey, B. Levin (Chicago, IL, USA)

    Objective: To examine differences between United States (US) and Latin American (LA) norms classifying cognitive impairment using standardized neuropsychological measures to assess cognition in Parkinson’s…
  • 2017 International Congress

    Nilotinib differentially affects oligomeric α-synuclein and reduces phosphorylated neurofilaments and motor symptoms in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, M. Hebron, Y. Torres-Yaghi, A. Lawler, T. Kimbason, N. Starr, B. Wilmarth, M. Arellano, A. Shekoyan, J. Ahn, C. Moussa (Washington, DC, USA)

    Objective: This is a retrospective biomarker study of an open-label clinical study to examine the safety and efficacy of lower doses (<50% of CML dose)…
  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 128
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley